<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883480</url>
  </required_header>
  <id_info>
    <org_study_id>SLAT</org_study_id>
    <nct_id>NCT00883480</nct_id>
  </id_info>
  <brief_title>Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma</brief_title>
  <acronym>SLAT</acronym>
  <official_title>Tratamiento Individualizado en funci칩n de Las Mutaciones en EGFR y Del Nivel de expresi칩n de BRCA1 en Pacientes Con Adenocarcinoma de pulm칩n Avanzado</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pharmacogenic, prospective, and multicenter study in patients with advanced lung
      adenocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacogenomic study, prospective, multicenter. Individualized treatment based on EGFR
      mutations and level of BRCA1 expression in patients with advanced lung adenocarcinoma
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumoral Response (RECIST criteria)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/day 1 x 4 cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel-Cisplatin</intervention_name>
    <description>Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine-Cisplatin</intervention_name>
    <description>Cisplatin 75 mg/ day 1 x 4 cycles
Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg/day x 21 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 18 years or more.

          -  Histologically confirmed diagnosis of non-small-cell lung carcinoma.(and
             indifferentiated and BAC histology).

               -  Only patients with advanced disease, defined as stage IV or IIIB with/without
                  pleural effusion, will be included.

               -  Tumor sample available.

               -  A measurable lesion, as defined by RECIST criteria.

               -  Karnofsky score 60% or more (ECOG &lt; 2).

               -  Patients should not have received previous treatment with chemotherapy or other
                  agents for disseminated disease. Chemotherapy is allowed if the initial diagnosis
                  of the patient is limited disease and the patient has received adjuvant or
                  neoadjuvant treatment.

          -  Patients with cerebral disease are permitted, without any time limitations after
             holocranial irradiation or complementary antiedema treatment.

          -  Patients with hepatical, renal and hematology normality values.

          -  Patients should sign an informed consent form before inclusion in the study that
             specifies that the clinical trial treatment entails consent for the analysis of
             biological samples of tumor and blood.

          -  Patients of childbearing age of either sex must use effective contraceptive methods
             (barrier methods or other birth control methods) before entering the study and while
             participating in the study.

          -  Patients must be available for clinical follow-up..

        Exclusion Criteria:

          -  Patients who have received an investigational medicinal product in the 21 days before
             inclusion in the study or antiEGFR receptor agent.

          -  Severe comorbidity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Rosell, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>ICO-HOSPITAL GERMANS TRIAS I PUJOL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ico-Hospital Universitarios Germans Trias I Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya</name>
      <address>
        <city>M치laga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <last_update_submitted>April 16, 2009</last_update_submitted>
  <last_update_submitted_qc>April 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rafael Rosell</name_title>
    <organization>Spanish Lung Cancer Group</organization>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

